ABBVIE INC. vs. DiaMedica Therapeutics Inc. Common Stock
ABBVIE INC. (ABBV) comes out ahead, leading on 3 of 5 compared factors.
Size & Scale
| ABBV | DMAC | |
|---|---|---|
| Market Cap | $441.94 billion | $370.47 million |
| Revenue (TTM) | $64.39 billion | — |
| Net Income (TTM) | $6.32 billion | $-37,541,000 |
ABBV leads on 2 of 2 size & scale factors.
Valuation
| ABBV | DMAC | |
|---|---|---|
| P/E Ratio | 70.27 | — |
| Price / Book | -75.06 | 9.66 |
| Price / Sales | 6.86 | — |
ABBV leads on 1 of 1 valuation factors.
Profitability
| ABBV | DMAC | |
|---|---|---|
| Net Margin | 9.81% | — |
| Return on Equity | -107.29% | -97.92% |
DMAC leads on 1 of 1 profitability factors.
Risk & Sentiment
| ABBV | DMAC | |
|---|---|---|
| Short Interest | 0.85% | 0.05% |
DMAC leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, DMAC overview, DMAC financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.